We are live on ! Find out more

POM

POMDOCTOR LIMITED Class A Ordinary Shares

POM

Market cap $4.53M

1.63 USD

-0.22

11.89%

At close Updated Nov 3, 11:06 AM EST

1 day

-11.89%

5 days

5.16%

1 month

75.29%

3 months

137.06%

6 months

-76.17%

Year to date

-72.23%

1 year

-98.39%

5 years

-97.75%

10 years

-97.75%

About: Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

Employees: 165

Healthcare Pharmaceutical Retailers

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements

GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letters (the "Letters") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") regarding deficiencies with respect to certain continued listing requirements of The Nasdaq Global Market. The first Letter notified the Company that, based upon the Company's MVLS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2)(A) to maintain market value of listed securities ("MVLS") of at least $50 million (the "MVLS Requirement").

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it has commenced to terminate its American Depositary Receipt program (the "ADR Program"), including the termination of the related deposit agreement, as amended, and list the Company's Class A ordinary shares directly on The Nasdaq Stock Market LLC ("Nasdaq"). The termination was previously approved by the board of directors of Pomdoctor on September 3, 2026 and approved by the Company's shareholders on a non-binding advisory basis at the extraordinary general meeting of shareholders held on September 30, 2026.

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management. For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows.

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination

GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 6, 2026. The Letter notified the Company that the closing bid price of the Company's American depositary shares (the "ADSs") had been below $1.00 per share for 30 consecutive business days, from August 24, 2026 through October 5, 2026.

POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination

POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization

GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI-enabled chronic disease management ecosystem, including further optimization of its proprietary AI chronic disease management system, expanded real-world data ("RWD") applications, and integrated in-hospital and out-of-hospital chronic disease management pilots.

POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization

POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model

GUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its differentiated "hardware + AI + payment" infrastructure model.

POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept.

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework.

POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement.

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along with pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

See News Rankings

Price charts implemented using Lightweight Charts™